Prognostic factors for patients with Hodgkin disease in first relapse

E. A. Healey, N. J. Tarbell, L. A. Kalish, B. Silver, D. S. Rosenthal, K. Marcus, L. N. Shulman, C. N. Coleman, G. Canellos, H. Weinstein, P. Mauch

Research output: Contribution to journalArticle

Abstract

Background. This study aims to identify factors that predict outcome after salvage therapy for patients with Hodgkin disease (HD) in first relapse. Methods. Between 1969 and 1985, 627 patients with Pathologic Stage IA-IIIB HD were treated at the Joint Center for Radiation Therapy. With a median follow- up time for survivors of 135 months, 138 patients (22%) have experienced relapse. One hundred twenty-seven of these were retreated with curative intent and form the basis of this report. Results. The complete response (CR) rate after retreatment was 79%. The 10-year actuarial freedom from second relapse (FSR) was 53%, and the 10-year survival rate from the time of first relapse was 57%. For patients experiencing relapse after initial radiation therapy (RT) alone (n = 110), the 10-year FSR and overall survival rates were 58% and 62%, respectively. Histologic type was the single most important prognostic factor for second CR rate, FSR, and survival. Patients with nodular sclerosis or lymphocyte predominant (NS/LP) histologic type had a 91% second CR rate, 67% 10-year FSR rate, and 75% 10-year survival rate, compared with 66%, 44%, and 43%, respectively, for patients with mixed cellularity or lymphocyte depleted (MC/LD) histologic type. For patients who experienced relapse after initial combined modality therapy (CMT; n = 17), the 10-year FSR and overall survival rates were 13% and 24%, respectively. Conclusion. This study demonstrates that patients who experience relapse after RT alone can be effectively salvaged with combination chemotherapy. The implications of these results for clinical decision making are discussed.

Original languageEnglish (US)
Pages (from-to)2613-2620
Number of pages8
JournalCancer
Volume71
Issue number8
StatePublished - 1993
Externally publishedYes

Fingerprint

Hodgkin Disease
Recurrence
Survival Rate
Radiotherapy
Lymphocytes
Salvage Therapy
Combined Modality Therapy
Retreatment
Sclerosis
Combination Drug Therapy
Survivors
Survival

Keywords

  • chemotherapy
  • histology
  • Hodgkin disease
  • prognostic factors
  • radiation therapy
  • relapse
  • salvage

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Healey, E. A., Tarbell, N. J., Kalish, L. A., Silver, B., Rosenthal, D. S., Marcus, K., ... Mauch, P. (1993). Prognostic factors for patients with Hodgkin disease in first relapse. Cancer, 71(8), 2613-2620.

Prognostic factors for patients with Hodgkin disease in first relapse. / Healey, E. A.; Tarbell, N. J.; Kalish, L. A.; Silver, B.; Rosenthal, D. S.; Marcus, K.; Shulman, L. N.; Coleman, C. N.; Canellos, G.; Weinstein, H.; Mauch, P.

In: Cancer, Vol. 71, No. 8, 1993, p. 2613-2620.

Research output: Contribution to journalArticle

Healey, EA, Tarbell, NJ, Kalish, LA, Silver, B, Rosenthal, DS, Marcus, K, Shulman, LN, Coleman, CN, Canellos, G, Weinstein, H & Mauch, P 1993, 'Prognostic factors for patients with Hodgkin disease in first relapse', Cancer, vol. 71, no. 8, pp. 2613-2620.
Healey EA, Tarbell NJ, Kalish LA, Silver B, Rosenthal DS, Marcus K et al. Prognostic factors for patients with Hodgkin disease in first relapse. Cancer. 1993;71(8):2613-2620.
Healey, E. A. ; Tarbell, N. J. ; Kalish, L. A. ; Silver, B. ; Rosenthal, D. S. ; Marcus, K. ; Shulman, L. N. ; Coleman, C. N. ; Canellos, G. ; Weinstein, H. ; Mauch, P. / Prognostic factors for patients with Hodgkin disease in first relapse. In: Cancer. 1993 ; Vol. 71, No. 8. pp. 2613-2620.
@article{e39710736d6f4f6bae05bba8c1c21aed,
title = "Prognostic factors for patients with Hodgkin disease in first relapse",
abstract = "Background. This study aims to identify factors that predict outcome after salvage therapy for patients with Hodgkin disease (HD) in first relapse. Methods. Between 1969 and 1985, 627 patients with Pathologic Stage IA-IIIB HD were treated at the Joint Center for Radiation Therapy. With a median follow- up time for survivors of 135 months, 138 patients (22{\%}) have experienced relapse. One hundred twenty-seven of these were retreated with curative intent and form the basis of this report. Results. The complete response (CR) rate after retreatment was 79{\%}. The 10-year actuarial freedom from second relapse (FSR) was 53{\%}, and the 10-year survival rate from the time of first relapse was 57{\%}. For patients experiencing relapse after initial radiation therapy (RT) alone (n = 110), the 10-year FSR and overall survival rates were 58{\%} and 62{\%}, respectively. Histologic type was the single most important prognostic factor for second CR rate, FSR, and survival. Patients with nodular sclerosis or lymphocyte predominant (NS/LP) histologic type had a 91{\%} second CR rate, 67{\%} 10-year FSR rate, and 75{\%} 10-year survival rate, compared with 66{\%}, 44{\%}, and 43{\%}, respectively, for patients with mixed cellularity or lymphocyte depleted (MC/LD) histologic type. For patients who experienced relapse after initial combined modality therapy (CMT; n = 17), the 10-year FSR and overall survival rates were 13{\%} and 24{\%}, respectively. Conclusion. This study demonstrates that patients who experience relapse after RT alone can be effectively salvaged with combination chemotherapy. The implications of these results for clinical decision making are discussed.",
keywords = "chemotherapy, histology, Hodgkin disease, prognostic factors, radiation therapy, relapse, salvage",
author = "Healey, {E. A.} and Tarbell, {N. J.} and Kalish, {L. A.} and B. Silver and Rosenthal, {D. S.} and K. Marcus and Shulman, {L. N.} and Coleman, {C. N.} and G. Canellos and H. Weinstein and P. Mauch",
year = "1993",
language = "English (US)",
volume = "71",
pages = "2613--2620",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Prognostic factors for patients with Hodgkin disease in first relapse

AU - Healey, E. A.

AU - Tarbell, N. J.

AU - Kalish, L. A.

AU - Silver, B.

AU - Rosenthal, D. S.

AU - Marcus, K.

AU - Shulman, L. N.

AU - Coleman, C. N.

AU - Canellos, G.

AU - Weinstein, H.

AU - Mauch, P.

PY - 1993

Y1 - 1993

N2 - Background. This study aims to identify factors that predict outcome after salvage therapy for patients with Hodgkin disease (HD) in first relapse. Methods. Between 1969 and 1985, 627 patients with Pathologic Stage IA-IIIB HD were treated at the Joint Center for Radiation Therapy. With a median follow- up time for survivors of 135 months, 138 patients (22%) have experienced relapse. One hundred twenty-seven of these were retreated with curative intent and form the basis of this report. Results. The complete response (CR) rate after retreatment was 79%. The 10-year actuarial freedom from second relapse (FSR) was 53%, and the 10-year survival rate from the time of first relapse was 57%. For patients experiencing relapse after initial radiation therapy (RT) alone (n = 110), the 10-year FSR and overall survival rates were 58% and 62%, respectively. Histologic type was the single most important prognostic factor for second CR rate, FSR, and survival. Patients with nodular sclerosis or lymphocyte predominant (NS/LP) histologic type had a 91% second CR rate, 67% 10-year FSR rate, and 75% 10-year survival rate, compared with 66%, 44%, and 43%, respectively, for patients with mixed cellularity or lymphocyte depleted (MC/LD) histologic type. For patients who experienced relapse after initial combined modality therapy (CMT; n = 17), the 10-year FSR and overall survival rates were 13% and 24%, respectively. Conclusion. This study demonstrates that patients who experience relapse after RT alone can be effectively salvaged with combination chemotherapy. The implications of these results for clinical decision making are discussed.

AB - Background. This study aims to identify factors that predict outcome after salvage therapy for patients with Hodgkin disease (HD) in first relapse. Methods. Between 1969 and 1985, 627 patients with Pathologic Stage IA-IIIB HD were treated at the Joint Center for Radiation Therapy. With a median follow- up time for survivors of 135 months, 138 patients (22%) have experienced relapse. One hundred twenty-seven of these were retreated with curative intent and form the basis of this report. Results. The complete response (CR) rate after retreatment was 79%. The 10-year actuarial freedom from second relapse (FSR) was 53%, and the 10-year survival rate from the time of first relapse was 57%. For patients experiencing relapse after initial radiation therapy (RT) alone (n = 110), the 10-year FSR and overall survival rates were 58% and 62%, respectively. Histologic type was the single most important prognostic factor for second CR rate, FSR, and survival. Patients with nodular sclerosis or lymphocyte predominant (NS/LP) histologic type had a 91% second CR rate, 67% 10-year FSR rate, and 75% 10-year survival rate, compared with 66%, 44%, and 43%, respectively, for patients with mixed cellularity or lymphocyte depleted (MC/LD) histologic type. For patients who experienced relapse after initial combined modality therapy (CMT; n = 17), the 10-year FSR and overall survival rates were 13% and 24%, respectively. Conclusion. This study demonstrates that patients who experience relapse after RT alone can be effectively salvaged with combination chemotherapy. The implications of these results for clinical decision making are discussed.

KW - chemotherapy

KW - histology

KW - Hodgkin disease

KW - prognostic factors

KW - radiation therapy

KW - relapse

KW - salvage

UR - http://www.scopus.com/inward/record.url?scp=0027467482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027467482&partnerID=8YFLogxK

M3 - Article

C2 - 8453585

AN - SCOPUS:0027467482

VL - 71

SP - 2613

EP - 2620

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -